Rapid high-performance liquid chromatographic assay for atovaquone.
A rapid high-performance liquid chromatography assay has been developed for the drug atovaquone, which is currently being used to treat Pneumocystis carinii pneumonia and Toxoplasma gondii encephalitis associated with the acquired immunodeficiency syndrome (AIDS). Protein is precipitated from plasma with acetonitrile-aqueous 1% acetic acid (85:15). The supernatant is assayed on a C6 column using methanol-10 mM triethylamine in aqueous 0.2% trifluoroacetic acid (76:24) with detection at 254 nm. The working assay range was 0.5 to 50 micrograms/ml. Recovery was 97% and the between-day coefficients of variation were 2.1% at 50 micrograms/ml and 10.3% at 1 microgram/ml. A number of drugs commonly used to treat AIDS and its complications did not interfere with the assay.
Hansson
A G
AG
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06520-8035, USA.
Mitchell
S
S
Jatlow
P
P
Rainey
P M
PM
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000935:Antifungal Agents / Q000097:blood* / Q000627:therapeutic use; D053626:Atovaquone; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D009285:Naphthoquinones / Q000097:blood* / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000935:Antifungal Agents; D009285:Naphthoquinones; D053626:Atovaquone